The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BWV | -94.74% | N/A | N/A | -100% |
| S&P | +14.77% | +87.2% | +13.35% | +59% |
Blue Water Biotech, Inc. is a biotechnology company, which engages in the research and development of transformational vaccines to prevent infectious diseases worldwide. Its platform includes the BWV Norovirus (NoV) S&P Nanoparticle Versatile Vaccine. Bioengineering the shell (S) and protruding (P) domains of the norovirus capsid protein, polyvalent nanoparticles and polymers/oligomers provide a versatile vaccine platform with wide applications. The company was founded by Joseph Hernandez on October 26, 2018 and is headquartered in Cincinnati, OH.
No news articles found for Onconetix.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $303.65K | -25.4% |
| Gross Profit | $268.89K | 256.6% |
| Gross Margin | 88.55% | 70.0% |
| Market Cap | $4.81M | -88.9% |
| Market Cap / Employee | $686.73K | 0.0% |
| Employees | 7 | -69.6% |
| Net Income | -$8,783.70K | -129.5% |
| EBITDA | -$2,065.85K | 15.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $836.56K | 145.0% |
| Accounts Receivable | $2.55K | -97.4% |
| Inventory | 0.2 | 24.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | -100.0% |
| Short Term Debt | $166.42K | -98.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -120.44% | -5.5% |
| Return On Invested Capital | -197.75% | -116.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3,177.83K | -176.6% |
| Operating Free Cash Flow | -$3,177.83K | -177.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.84 | 0.72 | 0.52 | 0.53 | -58.35% |
| Price to Sales | 2.93 | 0.74 | 2.04 | 3.57 | -1.63% |
| Price to Tangible Book Value | -16.89 | -2.09 | -0.17 | -0.26 | -90.36% |
| Enterprise Value to EBITDA | -11.55 | -6.20 | -8.69 | -1.79 | -82.83% |
| Return on Equity | -171.4% | -237.7% | -254.1% | -263.6% | 12.75% |
| Total Debt | $13.57M | $9.85M | $8.75M | $166.42K | -98.61% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
